Adding Olaratumab Dramatically Improves Survival in Soft-Tissue Sarcoma


Early trial results found that the addition of olaratumab to doxorubicin dramatically improves survival in patients with advanced soft-tissue sarcoma.

The addition of olaratumab to doxorubicin dramatically improves survival in patients with advanced soft-tissue sarcoma, according to the results of a randomized phase Ib/II trial (abstract 10501) presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 29 to June 2, in Chicago.

“Olaratumab is the first agent added to doxorubicin to improve overall survival in advanced/metastatic soft-tissue sarcoma in a randomized trial,” said lead author William D. Tap, MD, chief, sarcoma medical oncology service at Memorial Sloan Kettering Cancer Center in New York.

Olaratumab is a human anti-platelet–derived growth factor α (PDGFRα) monoclonal antibody. “PDGFRα is genetically altered and overexpressed in multiple tumor types, including certain sarcomas, and the expression is associated with increased metastatic potential,” Tap said.

Doxorubicin remains the standard of care for most metastatic soft-tissue sarcomas, but doxorubicin combinations have yet to improve overall survival over doxorubicin alone. Olaratumab has demonstrated antitumor activity alone or in combination with doxorubicin in human sarcoma models, he said.

This phase II trial randomized 133 unresectable/metastatic soft-tissue sarcoma patients (median age 58 years) to receive up to 8 cycles of doxorubicin 75 mg/m2 with or without olaratumab 15 mg/kg. In the combination arm, olaratumab monotherapy continued after doxorubicin until disease progression. In the doxorubicin-alone arm, patients could cross over to olaratumab at progression.

The patient characteristics were well balanced, he said. The majority had ECOG status of 0 or 1. About one-third had leiomyosarcoma.

The primary endpoint of progression-free survival was met. The median progression-free survival was 6.6 months in the combination arm and 4.1 months in the doxorubicin-alone arm (hazard ratio [HR] = 0.67). Interim overall survival also favored the combination arm (25 months vs 14.7 months; HR = 0.44).

Similarly, objective response rates were higher in the combination arm (18.8%) as compared to the doxorubicin-alone arm (12.3%).

More grade 3 or higher adverse events occurred in combination arm, including neutropenia (51.5% vs 33.8%), anemia (12.5% vs 7.7%), fatigue (9.4% vs 3.1%), and thrombocytopenia (9.4% vs 7.7%). The doxorubicin-alone arm induced more grade 3 or higher febrile neutropenia (13.8 vs 12.5%) and infections (10.8 vs 6.3%), as well as more adverse events leading to discontinuations (22% vs 13%).

In conclusion, Tap said: “Olaratumab added to doxorubicin achieved a statistically significant improvement of 10.3 months in median overall survival over doxorubicin alone, without an increase in serious toxicity. Despite higher cumulative doxorubicin exposure, the olaratumab plus doxorubicin combination had an acceptable and monitorable safety profile, including cardiac safety.”

Based on these data, olaratumab has received Breakthrough Therapy Designation from the US Food and Drug Administration. A phase III study is planned, he said.

ASCO discussant Laurence Baker, DO, professor of medical oncology at the University of Michigan, noted the “dramatic difference in overall survival” seen with olaratumab, commenting that the PDGFRα monoclonal antibody “shows great promise,” and that he is excited a phase III trial is planned.

Related Videos
The difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Future developments in the sarcoma space may also involve research on circulating tumor DNA and metabolic therapies, according to Brian Van Tine, MD, PhD.
Current research in the sarcoma space includes the development of treatment options such as T-cell therapies, and combinations such as TKIs/immunotherapy, according to Brian Van Tine, MD, PhD.
Brian Van Tine, MD, PhD, states that sitravatinib appears to be active and well tolerated among patients with dedifferentiated or well-differentiated liposarcoma.
Brian Van Tine, MD, PhD, also discusses how the treatment of desmoid tumors has evolved following data supporting the use of sorafenib in this population.
CAR T-cell therapies and immunotherapy agents may offer up new options and even become standard of care in certain sarcoma subtypes.
There are several novel treatments that may be beneficial in several sarcoma subtypes including CAR T-cell therapies and immune checkpoint inhibitors, according to Sandra P. D’Angelo, MD.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Related Content